Global Nucleoside Antiviral Drugs Market Growth 2025-2031
Description
The global Nucleoside Antiviral Drugs market size is predicted to grow from US$ 981 million in 2025 to US$ 1424 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.
Nucleoside antiviral drugs are a class of antiviral agents that mimic natural nucleosides and interfere with viral replication by being incorporated into viral DNA or RNA, leading to chain termination or inhibition of viral polymerase. These drugs are commonly used to treat infections caused by viruses such as HIV, hepatitis B, and herpes viruses.
United States market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nucleoside Antiviral Drugs players cover Greater Pharma, LBS Labs, GlaxoSmithKline, Lex Ano, Salutas, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Nucleoside Antiviral Drugs Industry Forecast” looks at past sales and reviews total world Nucleoside Antiviral Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Nucleoside Antiviral Drugs sales for 2025 through 2031. With Nucleoside Antiviral Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleoside Antiviral Drugs industry.
This Insight Report provides a comprehensive analysis of the global Nucleoside Antiviral Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleoside Antiviral Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleoside Antiviral Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleoside Antiviral Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleoside Antiviral Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleoside Antiviral Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Acyclovir
Zidovudine
Entecavir
Sofosbuvir
Other
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Greater Pharma
LBS Labs
GlaxoSmithKline
Lex Ano
Salutas
Novartis
Teva
Stada Nordic
Cimed Industria de Medicamentos
Reman Drug
L.E.T.I.
Nichi-Iko Pharmaceutical
Choseido Pharmaceutical
Shiono Kemikaru
Towa Yakuhin
Wockhardt
Takata Pharmaceutical
Aliud
Amneal Pharma
Apotex
Arrow
Laboratoires Servier
Sanofi
Mylan
Orion Pharma
Pfizer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleoside Antiviral Drugs market?
What factors are driving Nucleoside Antiviral Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleoside Antiviral Drugs market opportunities vary by end market size?
How does Nucleoside Antiviral Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Nucleoside antiviral drugs are a class of antiviral agents that mimic natural nucleosides and interfere with viral replication by being incorporated into viral DNA or RNA, leading to chain termination or inhibition of viral polymerase. These drugs are commonly used to treat infections caused by viruses such as HIV, hepatitis B, and herpes viruses.
United States market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nucleoside Antiviral Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nucleoside Antiviral Drugs players cover Greater Pharma, LBS Labs, GlaxoSmithKline, Lex Ano, Salutas, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Nucleoside Antiviral Drugs Industry Forecast” looks at past sales and reviews total world Nucleoside Antiviral Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Nucleoside Antiviral Drugs sales for 2025 through 2031. With Nucleoside Antiviral Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleoside Antiviral Drugs industry.
This Insight Report provides a comprehensive analysis of the global Nucleoside Antiviral Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleoside Antiviral Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleoside Antiviral Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleoside Antiviral Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleoside Antiviral Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleoside Antiviral Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Acyclovir
Zidovudine
Entecavir
Sofosbuvir
Other
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Greater Pharma
LBS Labs
GlaxoSmithKline
Lex Ano
Salutas
Novartis
Teva
Stada Nordic
Cimed Industria de Medicamentos
Reman Drug
L.E.T.I.
Nichi-Iko Pharmaceutical
Choseido Pharmaceutical
Shiono Kemikaru
Towa Yakuhin
Wockhardt
Takata Pharmaceutical
Aliud
Amneal Pharma
Apotex
Arrow
Laboratoires Servier
Sanofi
Mylan
Orion Pharma
Pfizer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleoside Antiviral Drugs market?
What factors are driving Nucleoside Antiviral Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleoside Antiviral Drugs market opportunities vary by end market size?
How does Nucleoside Antiviral Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
174 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Nucleoside Antiviral Drugs by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Nucleoside Antiviral Drugs by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
